Literature DB >> 25435117

Pediatric lymphomas and histiocytic disorders of childhood.

Carl E Allen1, Kara M Kelly2, Catherine M Bollard3.   

Abstract

Although there have been dramatic improvements in the treatment of children with non-hodgkin lymphoma, hodgkin lymphoma and histiocytic disorders over the past 3 decades, many still relapse or are refractory to primary therapy. In addition, late effects such as 2nd malignancies, cardiomyopathy and infertility remain a major concern. Thus, this review focuses on the current state of the science and, in particular, novel treatment strategies that are aimed at improving outcomes for all pediatric patients with lymphoma and histiocytic disorders while reducing treatment related morbidity.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anaplastic large cell lymphoma (ALCL); Burkitt lymphoma (BL); Diffuse large B-cell lymphoma (DLBCL); Hodgkin lymphoma (HL); Juvenile xanthoganuloma (JXG); Langerhans cell histiocytosis (LCH); Posttransplant lymphoproliferative disease (PTLD); Rosai-Dorfman disease (RDD)

Mesh：

Year:  2015        PMID： 25435117      PMCID： PMC4250829          DOI： 10.1016/j.pcl.2014.09.010

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN： 0031-3955            Impact factor:   3.278


  122 in total

1.  BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis.

Authors:  Felix Sahm; David Capper; Matthias Preusser; Jochen Meyer; Albrecht Stenzinger; Felix Lasitschka; Anna-Sophie Berghoff; Antje Habel; Marion Schneider; Andreas Kulozik; Ioannis Anagnostopoulos; Leonhard Müllauer; Gunhild Mechtersheimer; Andreas von Deimling
Journal:  Blood       Date:  2012-08-02       Impact factor: 22.113

2.  Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial.

Authors:  Ilske Oschlies; Wolfram Klapper; Martin Zimmermann; Matthias Krams; Hans-Heinrich Wacker; Birgit Burkhardt; Lana Harder; Reiner Siebert; Alfred Reiter; Reza Parwaresch
Journal:  Blood       Date:  2006-01-19       Impact factor: 22.113

3.  Langerin (CD207) staining in normal pediatric tissues, reactive lymph nodes, and childhood histiocytic disorders.

Authors:  Kudakwashe Chikwava; Ronald Jaffe
Journal:  Pediatr Dev Pathol       Date:  2004-11-08

4.  Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.

Authors:  Catherine Patte; Anne Auperin; Mary Gerrard; Jean Michon; Ross Pinkerton; Richard Sposto; Claire Weston; Martine Raphael; Sherrie L Perkins; Keith McCarthy; Mitchell S Cairo
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

5.  Prevalence and prognostic significance of Epstein-Barr virus infection in classical Hodgkin's lymphoma: a meta-analysis.

Authors:  Ju-Han Lee; Younghye Kim; Jung-Woo Choi; Young-Sik Kim
Journal:  Arch Med Res       Date:  2014-06-14       Impact factor: 2.235

6.  The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.

Authors:  Kerry J Savage; Stefano Monti; Jeffery L Kutok; Giorgio Cattoretti; Donna Neuberg; Laurence De Leval; Paul Kurtin; Paola Dal Cin; Christine Ladd; Friedrich Feuerhake; Ricardo C T Aguiar; Sigui Li; Gilles Salles; Francoise Berger; Wen Jing; Geraldine S Pinkus; Thomas Habermann; Riccardo Dalla-Favera; Nancy Lee Harris; Jon C Aster; Todd R Golub; Margaret A Shipp
Journal:  Blood       Date:  2003-08-21       Impact factor: 22.113

7.  Hodgkin's disease in the very young.

Authors:  S F Cleary; M P Link; S S Donaldson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-01-01       Impact factor: 7.038

8.  Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin's lymphoma of children: a report from the Childrens Cancer Study Group.

Authors:  A T Meadows; R Sposto; R D Jenkin; J H Kersey; R R Chilcote; S E Siegel; P F Coccia; J Rosenstock; K C Pringle; C J Stolar
Journal:  J Clin Oncol       Date:  1989-01       Impact factor: 44.544

9.  Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report.

Authors:  S Goldman; L Smith; J R Anderson; S Perkins; L Harrison; M B Geyer; T G Gross; H Weinstein; S Bergeron; B Shiramizu; W Sanger; M Barth; J Zhi; M S Cairo
Journal:  Leukemia       Date:  2012-09-03       Impact factor: 11.528

10.  Value of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan versus diagnostic contrast computed tomography in initial staging of pediatric patients with lymphoma.

Authors:  Gang Cheng; Sabah Servaes; Hongming Zhuang
Journal:  Leuk Lymphoma       Date:  2012-09-28
View more
  20 in total

Review 1.  Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective.

Authors:  Irtiza N Sheikh; Amr Elgehiny; Dristhi Ragoonanan; Kris M Mahadeo; Yago Nieto; Sajad Khazal
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

Review 2.  Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma.

Authors:  Kathleen M McCarten; Helen R Nadel; Barry L Shulkin; Steve Y Cho
Journal:  Pediatr Radiol       Date:  2019-10-16

3.  Five decades of low intensity and low survival: adapting intensified regimens to cure pediatric Burkitt lymphoma in Africa.

Authors:  Nmazuo W Ozuah; Joseph Lubega; Carl E Allen; Nader Kim El-Mallawany
Journal:  Blood Adv       Date:  2020-08-25

4.  Beyond Endemic Burkitt Lymphoma: Navigating Challenges of Differentiating Childhood Lymphoma Diagnoses Amid Limitations in Pathology Resources in Lilongwe, Malawi.

Authors:  Nader Kim El-Mallawany; Mercy Mutai; Idah Mtete; Satish Gopal; Christopher C Stanley; Peter Wasswa; Mary Mtunda; Mary Chasela; William Kamiyango; Jimmy Villiera; Yuri Fedoriw; Nathan D Montgomery; George N Liomba; Coxcilly Kampani; Robert Krysiak; Katherine D Westmoreland; Maria H Kim; Jeremy S Slone; Michael E Scheurer; Carl E Allen; Parth S Mehta; Peter N Kazembe
Journal:  Glob Pediatr Health       Date:  2017-06-23

5.  Primary gastric Burkitt lymphoma-induced anaemia: a case report and a literature review.

Authors:  Monika Kapitančukė; Agnija Vaščiūnaitė; Rasa Augustinienė; Jūratė Sakalinskienė; Gražina Kleinotienė
Journal:  Acta Med Litu       Date:  2018

6.  Residential Radon Exposure and Incidence of Childhood Lymphoma in Texas, 1995-2011.

Authors:  Erin C Peckham; Michael E Scheurer; Heather E Danysh; Joseph Lubega; Peter H Langlois; Philip J Lupo
Journal:  Int J Environ Res Public Health       Date:  2015-09-25       Impact factor: 3.390

Review 7.  Whole-body MRI in paediatric oncology.

Authors:  Rutger A J Nievelstein; Annemieke S Littooij
Journal:  Radiol Med       Date:  2015-12-02       Impact factor: 3.469

8.  Pediatric Pulmonary Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: A Case Report and Review of the Literature.

Authors:  Eric X Wei; Roberto F Silva; James D Cotelingam; Rodney E Shackelford
Journal:  Case Rep Pathol       Date:  2017-10-08

9.  Clinicopathological features and EBV infection status of lymphoma in children and adolescents in South China: a retrospective study of 662 cases.

Authors:  Changfei Qin; Yuhua Huang; Yanfen Feng; Min Li; Na Guo; Huilan Rao
Journal:  Diagn Pathol       Date:  2018-02-27       Impact factor: 2.644

Review 10.  MiRNA Dysregulation in Childhood Hematological Cancer.

Authors:  Jaqueline Carvalho de Oliveira; Gabriela Molinari Roberto; Mirella Baroni; Karina Bezerra Salomão; Julia Alejandra Pezuk; María Sol Brassesco
Journal:  Int J Mol Sci       Date:  2018-09-10       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.